IKBKE inhibits TSC1 to activate the mTOR/S6K pathway for oncogenic transformation
IKBKE (IKKε) has emerged as a key modulator of multiple substrates, controlling oncogenic pathways in various malignancies.
___
- AlQurashi N, Hashimi SM, Wei MQ (2013). Chemical inhibitors
and microRNAs (miRNA) targeting the mammalian target of
rapamycin (mTOR) pathway: potential for novel anticancer
therapeutics. Int J Mol Sci 14: 3874-3900.
- Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y,
Thai TC, Huang Y, Boyden M et al. (2014). Targeting an IKBKE
cytokine network impairs triple-negative breast cancer growth.
J Clin Invest 124: 5411-5423.
- Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni
F, Geremia R, Sette C (2008). Phosphorylation of eIF4E by
MNKs supports protein synthesis, cell cycle progression and
proliferation in prostate cancer cells. Carcinogenesis 29: 2279-
2288.
- Bodur C, Kazyken D, Huang K, Ekim Ustunel B, Siroky KA, Tooley
AS, Gonzalez IR, Foley DH, Acosta-Jaquez HA, Barnes TM et
al. (2018). The IKK-related kinase TBK1 activates mTORC1
directly in response to growth factors and innate immune
agonists. EMBO J 37: 19-38.
- Challa S, Guo JP, Ding X, Xu CX, Li Y, Kim D, Smith MA, Cress DW,
Coppola D, Haura EB, et al. (2016). IKBKE is a substrate of
EGFR and a therapeutic target in non-small cell lung cancer
with activating mutations of EGFR. Cancer Res 76: 4418-4429.
- Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP,
O’Neill L, Beyaert R, Piette J, Chariot A (2008). Are the IKKs
and IKK-related kinases TBK1 and IKK-epsilon similarly
activated? Trends Biochem Sci 33: 171-180.
- Cooper JM, Ou YH, McMillan EA, Vaden RM, Zaman A, Bodemann
BO, Makkar G, Posner BA, White MA (2017). TBK1 provides
context-selective support of the activated Akt/mTOR pathway
in lung cancer. Cancer Res 77: 5077-5094.
- Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N (2010).
Dissecting the role of mTOR: lessons from mTOR inhibitors.
Biochim Biophys Acta 1804: 433-439.
- Feng Z, Zhang H, Levine AJ, Jin S (2005). The coordinate regulation
of the p53 and mTOR pathways in cells. P Natl Acad Sci USA
102: 8204-8209.
- Göktuna SI, Canli O, Bollrath J, Fingerle AA, Horst D, Diamanti
MA, Pallangyo C, Bennecke M, Nebelsiek T, Mankan AK et
al. (2014). IKKα promotes intestinal tumorigenesis by limiting
recruitment of M1-like polarized myeloid cells. Cell Rep 7:
1914-1925.
- Göktuna SI, Shostak K, Chau TL, Heukamp LC, Hennuy B, Duong
HQ, Ladang A, Close P, Klevernic I, Olivier F et al. (2016).
The prosurvival IKK-related kinase IKKε integrates LPS and
IL17A signaling cascades to promote Wnt-dependent tumor
development in the intestine. Cancer Res 76: 2587-2599.
- Guo JP, Coppola D, Cheng JQ (2011). IKBKE protein activates
Akt independent of phosphatidylinositol 3-kinase/PDK1/
mTORC2 and the Pleckstrin homology domain to sustain
malignant transformation. J Biol Chem 286: 37389-37398.
- Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR,
Meyuhas O, Shokat KM, Ruggero D (2010). Genetic dissection
of the oncogenic mTOR pathway reveals druggable addiction
to translational control via 4EBP-eIF4E. Cancer Cell 17: 249-
261.
- Hsu S, Kim M, Hernandez L, Grajales V, Noonan A, Anver M,
Davidson B, Annunziata CM (2012). IKKε coordinates
invasion and metastasis of ovarian cancer. Cancer Res 72:
5494-5504.
- Huang J, Manning BD (2008). The TSC1–TSC2 complex: a molecular
switchboard controlling cell growth. Biochem J 412: 179-190.
- Huang J, Manning BD (2009). A complex interplay between Akt,
TSC2, and the two mTOR complexes. Biochem Soc Trans 37:
217-222.
- Huang K, Fingar DC (2014). Growing knowledge of the mTOR
signaling network. Semin Cell Dev Biol 36: 79-90.
- Inoki K, Corradetti MN, Guan KL (2005). Dysregulation of the TSC-
mTOR pathway in human disease. Nat Genet 37: 19-24.
- Inoki K, Li Y, Xu T, Guan KL (2003a). Rheb GTPase is a direct target
of TSC2 GAP activity and regulates mTOR signaling. Genes
Dev 17: 1829-1834.
- Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002). TSC2 is phosphorylated
and inhibited by Akt and suppresses mTOR signalling. Nat Cell
Biol 4: 648-657.
- Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q,
Bennett C, Harada Y, Stankunas K et al. (2006). TSC2 integrates
Wnt and energy signals via a coordinated phosphorylation by
AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
- Inoki K, Zhu T, Guan KL (2003b). TSC2 mediates cellular energy
response to control cell growth and survival. Cell 115: 577-590.
- Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson
RB (2007). Coordinate regulation of ribosome biogenesis and
function by the ribosomal protein S6 kinase, a key mediator of
mTOR function. Growth Factors 25: 209-226.
- Kim JY, Beg AA, Haura EB (2013). Non-canonical IKKs, IKKε and
TBK1, as novel therapeutic targets in the treatment of non-
small cell lung cancer. Expert Opin Ther Tar 17: 1109-1112.
- Laplante M, Sabatini DM (2012). mTOR signaling in growth control
and disease. Cell 149: 274-293.
- Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, Sun HL, Li LY,
Ping B, Huang WC et al. (2007). IKKβ suppression of TSC1
links inflammation and tumor angiogenesis via the mTOR
pathway. Cell 130: 440-455.
- Lu J, Yang Y, Guo G, Liu Y, Zhang Z, Dong S, Nan Y, Zhao Z, Zhong
Y, Huang Q (2017). IKBKE regulates cell proliferation and
epithelial–mesenchymal transition of human malignant
glioma via the Hippo pathway. Oncotarget 8: 49502-49514.
- Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005).
Phosphorylation and functional inactivation of TSC2 by Erk
implications for tuberous sclerosis and cancer pathogenesis.
Cell 121: 179-193.
- Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC
(2002). Identification of the tuberous sclerosis complex-2
tumor suppressor gene product tuberin as a target of the
phosphoinositide 3-kinase/akt pathway. Mol Cell 10: 151-162.
- Niederberger E, Moser CV, Kynast KL, Geisslinger G (2013). The
non-canonical IκB kinases IKKε and TBK1 as potential targets
for the development of novel therapeutic drugs. Curr Mol Med
13: 1089-1097.
- Péant B, Gilbert S, Le Page C, Poisson A, L’Ecuyer E, Boudhraa Z,
Bienz MN, Delvoye N, Saad F, Mes-Masson AM (2017). IκB-
Kinase-epsilon (IKKε) over-expression promotes the growth of
prostate cancer through the C/EBP-β dependent activation of
IL-6 gene expression. Oncotarget 8: 14487-14501.
- Potter CJ, Pedraza LG, Xu T (2002). Akt regulates growth by directly
phosphorylating Tsc2. Nat Cell Biol 4: 658-665.
- Rajurkar M, Dang K, Fernandez-Barrena MG, Liu X, Fernandez-
Zapico ME, Lewis BC, Mao J (2017). IKBKE is required during
KRAS-induced pancreatic tumorigenesis. Cancer Res 77: 320-
329.
- Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004). Tumor-
promoting phorbol esters and activated Ras inactivate the
tuberous sclerosis tumor suppressor complex via p90 ribosomal
S6 kinase. P Natl Acad Sci USA 101: 13489-13494.
- Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G
(2002). Regulation of an activated S6 kinase 1 variant reveals a
novel mammalian target of rapamycin phosphorylation site. J
Biol Chem 277: 20104-20112.
- Saxton RA, Sabatini DM (2017). mTOR signaling in growth,
metabolism, and disease. Cell 168: 960-976.
- She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit
DB, Rosen N (2010). 4E-BP1 is a key effector of the oncogenic
activation of the AKT and ERK signaling pathways that
integrates their function in tumors. Cancer Cell 18: 39-51.
- Shen RR, Hahn WC (2011). Emerging roles for the non-canonical
IKKs in cancer. Oncogene 30: 631-641.
- Sommese RF, Sivaramakrishnan S (2016). Substrate affinity
differentially influences protein kinase C regulation and
inhibitor potency. J Biol Chem 291: 21963-21970.
- Sun Z, Wang Z, Liu X, Wang D (2015). New development of inhibitors
targeting the PI3K/AKT/mTOR pathway in personalized
treatment of non-small-cell lung cancer. Colloq Inse 26: 1-14.
- Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, Wang CY,
Guan KL (2011). IκB kinase ε and TANK-binding kinase 1
activate AKT by direct phosphorylation. P Natl Acad Sci USA
108: 6474-6479.
- Zhao P, Wong KI, Sun X, Reilly SM, Uhm M, Liao Z, Skorobogatko
Y, Saltiel AR (2018). TBK1 at the crossroads of inflammation
and energy homeostasis in adipose tissue. Cell 172: 731-743.
- Zoncu R, Sabatini DM, Efeyan A (2011). mTOR: From growth signal
integration to cancer, diabetes and ageing. Nat Revs Mol Cell
Biol 12: 21-35.
- Zubair H, Azim S, Srivastava SK, Ahmad A, Bhardwaj A, Khan MA,
Patel GK, Arora S, Carter JE, Singh S et al. (2016). Glucose
metabolism reprogrammed by overexpression of IKKε
promotes pancreatic tumor growth. Cancer Res 76: 7254-7264.